Compare Page
CJC-1295 vs Sermorelin
Quick verdict: CJC-1295 vs Sermorelin is a duration-of-action comparison within the GHRH-analog class. Both CJC-1295 and sermorelin activate the GHRH receptor to stimulate pulsatile growth hormone release, but they differ dramatically in pharmacokinetics. CJC-1295 (with DAC) has a half-life of 5-8 days, producing sustained 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 elevation from a single injection.[1] Sermorelin (GRF 1-29) uses the native, unmodified GHRH sequence with a half-life of just 10-20 minutes, requiring more frequent administration but producing sharper, more natural GH pulses.[2] Sermorelin has the longest clinical history (former FDA approval as Geref®) and the Khorram aging studies showing multi-system benefits in elderly subjects.[3] CJC-1295 has the strongest human pharmacokinetic data for sustained GH/IGF-1 elevation.[1]
Read the full peptide profiles: CJC-1295 and Sermorelin.
At a Glance: CJC-1295 vs Sermorelin
How They Work
CJC-1295 and sermorelin both activate the same GHRH receptor on anterior pituitary somatotroph cells — the key difference is what happens after receptor binding. Sermorelin is the native human GHRH(1-29) sequence: the biologically active portion of the 44-amino-acid growth hormone-releasing hormone. It retains full receptor activity but is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) enzymes, giving it a half-life of only 10-20 minutes. This means sermorelin produces sharp, discrete GH pulses that closely mirror the body’s endogenous GHRH secretory pattern.[2][3]
CJC-1295 is an engineered improvement on the same sequence. The first 29 amino acids are modified with DPP-IV-resistant substitutions, preventing enzymatic degradation and extending the half-life. In the DAC (Drug Affinity Complex) version, a reactive linker enables covalent binding to serum albumin, further extending the half-life to approximately 5-8 days. Teichman et al. (2006) demonstrated in healthy human subjects that a single CJC-1295 (DAC) injection produced sustained 2- to 10-fold GH increases persisting up to 6 days, with 1.5- to 3-fold IGF-1 elevation lasting 9-11 days after multiple doses.[1]
Both compounds preserve pulsatile GH secretion — Ionescu & Bhatt (2006) confirmed that pulsatility is maintained during CJC-1295 stimulation.[4] The practical question is whether sustained baseline elevation (CJC-1295) or sharp natural-pattern pulses (sermorelin) better matches the research objective. For the complementary GH secretagogue pathway comparison, see Ipamorelin vs Sermorelin. For the other major GHRH analog, see Ipamorelin vs Tesamorelin.
Evidence Comparison
Sermorelin has deeper clinical outcome data. The Khorram et al. (1997) aging studies remain landmark: 16 weeks of GRF(1-29) in men and women aged 55-71 produced significant increases in 24-hour GH secretion, elevated IGF-1, increased lean body mass, reduced body fat, and enhanced immune function — including improved NK cell activity and lymphocyte proliferation.[3][5] These multi-system outcome data are unmatched by CJC-1295. Sermorelin’s former FDA approval (Geref®, 1997-2008) provides additional regulatory safety confidence.[2]
CJC-1295 has stronger pharmacokinetic characterisation. The Teichman (2006) human study precisely documented GH and IGF-1 elevation profiles, dose-response relationships, and duration of action — providing the clearest picture of sustained GHRH-pathway stimulation available in the literature.[1] Sackmann-Sala et al. (2009) showed measurable serum protein changes following CJC-1295 administration in healthy subjects.[6] However, clinical outcome studies — body composition, recovery, aging endpoints — comparable to sermorelin’s Khorram data are not available for CJC-1295.
The evidence trade-off: sermorelin has outcome data (lean mass, immune function, body fat) from controlled human studies; CJC-1295 has superior pharmacokinetic data but limited clinical outcome evidence. For the GHRH analog with the strongest clinical evidence overall, tesamorelin (FDA-approved, JAMA and Lancet HIV RCTs) surpasses both.
When Each Fits Better
CJC-1295 may be the stronger fit when:
- Sustained GH/IGF-1 elevation is desired — the DAC version provides days of activity from a single injection[1]
- Less frequent administration is important — weekly or twice-weekly dosing schedules
- Combination with a GH secretagogue (ipamorelin) is planned — CJC-1295 provides sustained GHRH-pathway stimulation alongside pulsatile GHS-R1a input
- Pharmacokinetic precision matters — the Teichman study provides the most detailed human PK data in the class[1]
Sermorelin may be the stronger fit when:
- Natural-pattern GH pulsatility is specifically desired — sermorelin uses the native sequence for the most physiological release pattern[2]
- Clinical safety pedigree is important — former FDA approval provides the longest regulatory track record[2][3]
- Aging and longevity research is the context — Khorram studies provide the strongest human aging data[3][5]
- Immune function endpoints are relevant — documented NK cell and lymphocyte improvements[5]
Head-to-Head
No direct head-to-head trial between CJC-1295 and sermorelin has been published. Both activate the same GHRH receptor, so the fundamental pharmacological action is identical — the difference is kinetic, not mechanistic. CJC-1295’s engineering modifications solve sermorelin’s key limitation (rapid degradation) but introduce a different GH pattern (sustained vs pulsatile).
The open question in GHRH-analog research is whether sustained GH/IGF-1 baseline elevation (CJC-1295 with DAC) or sharp natural-pattern pulses (sermorelin, CJC-1295 without DAC) produces better long-term outcomes for body composition, recovery, and aging endpoints. This has not been tested directly. The no-DAC version of CJC-1295 (Mod GRF 1-29) sits between the two: it has the DPP-IV-resistant modifications (~30-minute half-life) without albumin binding, producing more defined pulses than DAC but longer than sermorelin.
For most research contexts, the practical decision often comes down to dosing convenience (CJC-1295 with DAC: weekly) versus physiological mimicry (sermorelin: daily bedtime). Both approaches are supported by reasonable evidence and pharmacological rationale, and neither has been shown superior in clinical outcome comparisons.
FAQ
Are CJC-1295 and sermorelin the same thing?
They activate the same receptor but are different molecules. Sermorelin is the native, unmodified GHRH(1-29) sequence. CJC-1295 is a modified version with amino acid substitutions that resist DPP-IV degradation, plus (in the DAC version) an albumin-binding complex. The result: sermorelin acts for minutes; CJC-1295 acts for days.[1][2]
Which produces more growth hormone?
CJC-1295 (with DAC) produces more total GH exposure over time due to its extended duration. Teichman et al. showed 2-10x GH increases lasting up to 6 days.[1] Sermorelin produces sharp GH peaks that dissipate within hours.[2] Whether total GH exposure or peak amplitude matters more depends on the research endpoint.
What is CJC-1295 with DAC vs without DAC?
CJC-1295 with DAC (Drug Affinity Complex) binds to serum albumin, extending the half-life to 5-8 days. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) has the DPP-IV-resistant amino acids but no albumin binding — half-life ~30 minutes. The no-DAC version produces sharper, shorter GH pulses more similar to sermorelin’s pattern.[1]
Can either be combined with ipamorelin?
Yes, the pharmacological rationale is well-grounded. Both CJC-1295 and sermorelin work through the GHRH receptor, while ipamorelin works through the GHS-R1a (ghrelin receptor). These are independent receptor inputs on the same pituitary cell, theoretically producing synergistic GH release. The CJC-1295 no-DAC + ipamorelin combination is the most commonly discussed pairing for timing alignment.[1]
References
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683.
- Geref (sermorelin) prescribing information and FDA approval history. PMID: 9141536.
- Khorram O, et al. Two years of treatment with recombinant human GH-releasing hormone in age-advanced men and women. J Clin Endocrinol Metab. 1997. PMID: 14610297.
- Ionescu M, Bhatt DL. Pulsatile GH secretion is preserved during CJC-1295 stimulation. 2006.
- Khorram O, et al. Activation of immune function by GHRH administration in age-advanced adults. PMID: 8707960.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.